Source - LSE Regulatory
RNS Number : 9932R
Hikma Pharmaceuticals Plc
11 March 2021
 

London, 11 March 2021 - On 26 January 2021, Hikma Pharmaceuticals PLC (Hikma) announced that it had entered into a non-binding term sheet with GlaxoSmithKline PLC (GSK) for the purposes of potentially acquiring GSK's pharmaceutical and consumer businesses in Egypt and its pharmaceutical business in Tunisia (the Proposed Transaction).

Hikma today confirms that both companies have agreed to cease discussions regarding the Proposed Transaction and, accordingly, Hikma will not be launching a Mandatory Tender Offer process to acquire the shares in GlaxoSmithKline SAE Egypt.

 

- ENDS -

 

Enquiries        

Hikma Pharmaceuticals PLC   

Susan Ringdal

EVP, Strategic Planning and Global Affairs

 

Layan Kalisse

Investor Relations Analyst

+44 (0)20 7399 2760/ +44 7776 477050

uk-investors@hikma.uk.com

 

 

+44 (0)20 7399 2788 / +44 (0)7970 709912

 

 

Mona Abdallah

Communication Director - MENA 

+962 7 96777710

mena_communications@hikma.com

 

Teneo (Press):

Charles Armitstead/ Camilla Cunningham                                    +44 (0)7703 330 269/ +44 (0)7464 982 426 

 

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJBMJTMTJBBJB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Hikma Pharmaceuticals PLC (HIK)

+38.50p (+2.05%)
delayed 13:49PM